Apimeds Pharmaceuticals US (APUS) Return on Equity (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) reported Return on Equity of 0.0% for Q4 2025, down 1.0% on a YoY basis from 0.0% in Q4 2024, and up 74.14% quarter-over-quarter from 0.01% in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Return on Equity (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US has reported Return on Equity for 2 years, with the latest figure at 0.0% in Q4 2025.
- For the quarter ending Q4 2025, Return on Equity fell 1.0% year-over-year to 0.0%; the trailing twelve-month figure through Dec 2025 stood at 0.0% (down 1.0% YoY), and the FY2025 full-year result was 0.0%, down 2.0% from the prior year.
- Return on Equity for Q4 2025 stood at 0.0%, up from 0.01% in the prior quarter.
- The five-year high for Return on Equity was 0.01% in Q3 2024, with the low at 0.01% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 0.00% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 0.01% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 0.00% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 0.00% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 0.00% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 0.00% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 0.00% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 0.00% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 0.00% |
| 10 | Apimeds Pharmaceuticals US | 13.93 Mn | 10.29 Mn | - | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | -0.01% |
| Jun 30, 2025 | -0.01% |
| Mar 31, 2025 | 0.01% |
| Dec 31, 2024 | 0.01% |
| Sep 30, 2024 | 0.01% |